Enter the last name, specialty or keyword for your search below.
| Description: | Open label, randomized controlled trial that seeks to evaluate the utility of a cell-based liver assist device in patients with alcoholic hepatitis. |
| PI: | Kirti Shetty, MD |
| NCT: | NCT01829347 |
| Contact: | Suburban Hospital — Kate Levy 301-896-2672 |
| Description: | Placebo controlled, randomized trial in patients with cirrhosis and hepatic encephalopathy requiring hospitalization. |
| PI: | Kirti Shetty, MD |
| NCT: | NCT01966419 |
| IRB: | IRB00035034 |
| Contact: | Sibley Memorial Hospital — Kate Levy 202-660-5571 |
| Description: | A phase 2 B study of hepatitis C immunoglobulin in hepatitis C positive recipients undergoing liver transplantation. |
| PI: | Kirti Shetty, MD |
| NCT: | NCT01804829 |
| Contact: | Johns Hopkins Hospital — Mina Attia 443-287-8816 Sibley Memorial Hospital — Kate Levy 202-660-5571 |
| Description: | Registry trial which aims to collate information on patients with hepatic encephalopathy, managed both inpatient and in the clinic in terms of symptoms, medications, provider documentation. |
| PI: | Kirti Shetty, MD |
| Contact: | Sibley Memorial Hospital — Kate Levy 202-660-5571 |
| Description: | A placebo-controlled, randomized trial in patients with cirrhosis and portal hypertension who will be administered a novel anti-fibrotic, caspase inhibitor. |
| PI: | Kirti Shetty, MD |
| NCT: | NCT02230683 |
| Contact: | Sibley Memorial Hospital — Kate Levy 202-660-5571 |
| Description: | A Phase 1 study to assess the safety and tolerability of high dose vitamin D in cirrhosis |
| PI: | Kirti Shetty, MD |
| NCT: | NCT01956864 |
| Contact: | Sibley Memorial Hospital — Kate Levy 202-660-5571 |
| Description: | Efficacy and safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in chronic hepatitis C participants with Child-Pugh (CP)-B hepatic insufficiency. |
| PI: | Saleh Alqahtani, MD |
| NCT: | NCT02115321 |
| Description: | This study evaluates the efficacy and safety of Cenicriviroc for the treatment of NASH in adult subjects with liver fibrosis. |
| PI: | Saleh Alqahtani, MD |
| NCT: | NCT02217475 |
| Description: | This study evaluates efficacy and safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis. |
| PI: | Mark Sulkowski, MD |
| NCT: | NCT02201901 |
| Description: | A Phase 2, multicenter, open-label study to investigate the safety and efficacy of Sofosbuvir/Ledipasvir fixed-dose combination + Ribavirin administered in subjects infected with chronic HCV who have advanced liver disease or are post-liver transplant. |
| PI: | Mark Sulkowski, MD |
| NCT: | NCT01938430 |
1. DEBDOX study, J1306, NCT 02007954
This study investigates the safety and feasibility of novel, small drug eluting beads (70-150 micron) in patients with HCC.
PI: Jean-Francois Geschwind, MD
2. Therasphere Dose Distribution study, J1289, not listed on NCT
This study evaluates the dosing distribution to tumor and normal liver during Therasphere procedures.
PI: Jean-Francois Geschwind, MD
3. Conventional TACE with PK, J14131, NCT# pending
This study evaluates the pharmacokinetics (PK) of doxorubicin following conventional TACE, to determine if newer TACE administration techniques result in lower systemic exposure of doxorubicin.
PI: Jean-Francois Geschwind, MD
4. Lipiodol study, J12115, NCT01877187 This study investigates whether lipiodol, the carrier of the chemotherapy drugs used for TACE procedures, can be used as a biomarker of tumor response.
PI: Jean-Francois Geschwind, MD
5. 3D Roadmap, J11113, NCT01818440
This study is investigating the optimal imaging to use during TACE procedures, the current standard or a newer ‘3D roadmap’ imaging software.
PI: Jean-Francois Geschwind, MD
6. ACRIN, 6690
Prospective, multicenter comparison of CT scan vs MRI of liver for hepatocellular carcinoma in orthotopic liver transplantation (OLT) allocation.
PI: Kirti Shetty, MD
7. Sorafenib plus doxorubicin study, ECALGB80802, NCT01015833
Phase 3, randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced HCC.
PI: David Cosgrove, MD
8. ADI PEG20 study, J1209, NCT01287585
Randomized, placebo-controlled, phase 3 trial of ADI PEG20 versus placebo in patients with advanced HCC who have failed prior systemic therapy
PI: David Cosgrove, MD
9. EDT study, J1271, NCT01642186
A randomized, 3-arm study of everolimus, estrogen deprivation therapy (EDT) and everolimus plus EDT in patients with unresectable fibrolamellar carcinoma (FLC)
PI: David Cosgrove, MD
10. Lirilumab study, J1282, NCT01714739
A phase 1, dose escalation and cohort expansion study of the safety and efficacy of anti-Kir (Lirilumab) in combination with anti-PD1 (Nivolumab) in advanced HCC.
PI: William Sharfman
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
